CCF Webinar: Investigational treatment for KRAS-Mutated Cholangiocarcinoma – An Unmet Need
There are currently no approved therapies for patients with KRAS-mutated cholangiocarcinoma. In this webinar, you will learn about an ongoing Phase 1b/2a study that is aimed to evaluate the combination of GNS561, an autophagy inhibitor, and trametinib, a MEK-inhibitor, as a potential novel treatment for patients with unresectable or metastatic KRAS-mutated cholangiocarcinoma.
CCF Meeting: Navigating a Cholangiocarcinoma Diagnosis: Resource Roadmap
The CCF Advocacy team has developed the Navigating a Cholangiocarcinoma Diagnosis: Resource Roadmap Workbook as a roadmap for patients and caregivers to use as they navigate a cholangiocarcinogcoma (CCA) diagnosis. Each resource includes journal pages for notes. We understand that you’re having to absorb a lot of information at once. Notes for yourself and questions […]